ABL1 and neoplasm: Although ETV6-ABL1-driven neoplasms are well responsive to ATP-competitive TKI such as imatinib, nilotinib and dasatinib, nothing is known to the best of our knowledge about the effects of allosteric inhibition on ETV6-ABL1.